FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 195 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Celebrating 75 years of NHS cancer care July 5, 2023 In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer January 12, 2023 Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι... June 24, 2019 FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia June 2, 2022 Load more HOT NEWS New on NCI’s Websites for June 2020 EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC Prognostic Role of Plasmatic BRAF Allele Fraction for Survival in Patients...
